BDSI sights the results of the evaluation as very encouraging.

BioDelivery Sciences updates on Clonidine Topical Gel Stage 3 trial for PDN treatment BioDelivery Sciences International, Inc. announced today that it has finished a pre-specified interim evaluation of the ongoing preliminary pivotal Stage 3 trial for Clonidine Topical Gel for the treating unpleasant diabetic neuropathy . The interim evaluation was performed on data from the initial 50 percent of sufferers who completed the analysis. The objective of the interim evaluation was to permit for an example size adjustment if essential to maintain suitable statistical capacity to detect a treatment impact between Clonidine Topical Gel and placebo. BDSI sights the results of the evaluation as very encouraging.Eugene Braunwald, the Distinguished Hersey Professor of Medicine at Harvard Medical School, and Chairman of the TIMI Study Group at the Brigham and Women’s Hospital; and Dr. Alberto Zanchetti, Professor Emeritus of Internal Medication at the University of Milan and Scientific Director of the Istituto Auxologico Italiano, will co-seat a symposium titled Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure at the European Society of Cardiology Congress 2011 in Paris.

Other Posts From "laboratory":

Related Posts